The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Isocitrate Dehydrogenase (IDH) Inhibitors Market By 2030 Starting From Its 2026 Size?
The market for isocitrate dehydrogenase (idh) inhibitors has experienced rapid expansion in its size over recent years. This market is projected to expand from $2.46 billion in 2025 to reach $3.13 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 26.8%. Historically, the growth witnessed in this sector can be ascribed to several factors, including advancements in cancer genomics research, the presence of unmet needs in oncology, the emergence of mutation-driven drug discovery, increased adoption within hospital oncology departments, and the expansion of clinical trials.
The market for isocitrate dehydrogenase (idh) inhibitors is projected to experience substantial expansion over the coming years. This market is anticipated to reach $8.02 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.6%. Factors contributing to this growth during the projected period include developments in precision medicine, oncology treatments guided by biomarkers, innovative drug pipelines for rare cancers, the emergence of combination cancer therapies, and robust regulatory backing for targeted medications. Key trends expected during the forecast timeframe encompass the wider adoption of targeted oncology therapies, an uptick in drug development based on genetic mutations, a heightened emphasis on treating rare cancers, the expanding application of precision oncology diagnostics, and progress in small molecule cancer inhibitors.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp
What Drivers Are Shaping The Future Growth Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
The rising incidence of acute myeloid leukemia is projected to stimulate the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is defined as a rapidly advancing cancer of the blood and bone marrow, characterized by the quick proliferation of abnormal white blood cells that hinder regular blood cell formation. This increased occurrence of AML is attributed to the growing aging population, as older individuals are at a higher risk of developing this aggressive blood cancer due to age-related shifts in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors are effective in treating acute myeloid leukemia by blocking mutant IDH enzymes, thereby restoring normal blood cell development and slowing the growth of leukemia cells. For example, a report from the Australia-based non-profit Leukaemia Foundation in February 2023 indicated that from 2022 to 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are predicted to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Therefore, the increasing frequency of acute myeloid leukemia is expected to significantly drive the growth of the isocitrate dehydrogenase (IDH) inhibitors market.
Which Segment Categories Define The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications
Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers
What Major Market Trends Are Driving Changes In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
Companies operating within the isocitrate dehydrogenase (IDH) inhibitors market are primarily focused on securing regulatory approvals. This strategy aims to broaden the clinical application of their therapies, hasten market entry, and gain a competitive edge in treating IDH-mutant cancers. Regulatory approvals represent official consent from health authorities, enabling a drug’s marketing and use after its safety and effectiveness are confirmed. For example, in August 2024, Servier Laboratoires, a pharmaceutical company based in France, received FDA approval for VORANIGO (vorasidenib) tablets. This marked its introduction as the first targeted therapy for patients diagnosed with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly extends progression-free survival, as demonstrated in the Phase 3 INDIGO trial, where patients experienced a median progression-free survival of 27.7 months compared to 11.1 months for those receiving placebo. VORANIGO provides a convenient and well-tolerated option with manageable side effects, representing a significant breakthrough for a patient population with previously limited treatment options.
Who Are The Top Companies Competing In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC
Read the full isocitrate dehydrogenase (idh) inhibitors market report here:
Which Geographic Regions Are Influencing Demand In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Isocitrate Dehydrogenase (IDH) Inhibitors Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24577&type=smp
Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2026, By The Business Research Company
Histone Deacetylase Inhibitors Market Report 2026
Metabolic Disorders Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Proton Pump Inhibitors Market Report 2026
https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model